Horizon Pharma plc Presents Results from an Open-Label Study on the Use of PROCYSBI® (cysteamine bitartrate) Delayed-Release Capsules in Treatment-Naïve Children Younger than 6 Years of Age

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/29/2026

1. LFTO
2. QNT
3. INIO
4. AADX
5. HONA
6. CMCSA
7. ABBV
8. PLTR
9. MLM
10. KRG

Go back to Horizon Pharma plc Presents Results from an Open-Label Study on the Use of PROCYSBI® (cysteamine bitartrate) Delayed-Release Capsules in Treatment-Naïve Children Younger than 6 Years of Age

Horizon Pharma (HZNP) PT Raised to $21 at Jefferies; Reiterates Buy

November 7, 2017 8:34 AM EST

Jefferies raised its price target on Horizon Pharma (NASDAQ: HZNP) to $21.00 (from $16.00) while maintaining a Buy rating following the company's 3Q earnings report.

Including the upside from the Q3 results and expected shift in operating expenses from Q3 to Q4, Jefferies raised... More